Beijing Strong Biotechnologies, Inc.
九强生物
300406
Shenzhen Stock Exchange
Company Profile
(1) Large scale, advanced technology, excellent quality As a domestic player in the in vitro diagnostics industry, BSBE is committed to establishing an outstanding biochemistry testing platform. Currently, BSBE possess a comprehensive range of biochemistry diagnostic reagents and fully automated biochemistry analyzers. BSBE’s biochemistry development technology platform related techniques are at the forefront both domestically and internationally, ensuring the provision of consistently stable and reliable products. Through years of steady development and accumulation, BSBE has built a global marketing and service network, positioning itselves as a leader in the field of biochemistry. (2) Comprehensive range of analytes BSBE has been focusing on the research and development of in vitro diagnostic products, with a dedicated team of professionals. The product registration certificates by SFDA cover a wide range of products, and the company is particularly known for continuously introducing new testing projects. (3) "Running with the giants"- Expanding into the international market and demonstrating technical prowess Since 2013, BSBE has progressively established strategic partnerships with well-known domestic and international enterprises such us Abbott, Roche, Hitachi, and Mindray. The “LICENSE, TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT” signed with Abbott in 2016 marked a pioneering step for China’s IVD technology exports, and also laid the foundation for long-term cooperation with foreign enterprises. After more than a decade of substantial development, BSBE has grown to become one of China's leading IVD product manufacturers, gradually gaining a foothold in the international IVD market. (4) Bright prospects for future growth Leveraging the position as a listed company, BSBE will intensify efforts to expand externally and maintain its growth trajectory.
Full description
Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) is one of China's leading provider of in-vitro diagnostics (IVD) products and services. Established in 2001, BSBE focuses on the R&D, manufacturing and sales of IVD products that are at the forefront of international standards.And achieved successful listing on the GEM in Shenzhen under the stock code 300406 in 2014. As a Chinese leader in IVD filed, BSBE is engaged in developing the best IVD testing platform.Up to now, BSBE has developed systems for biochemical testing, coagulation testing, blood typing, POCT testing, pathology diagnostic, and liquid biopsy CTC detection.. Thanks to the steady progress and extensive experience over the years, BSBE has established a global sales and marketing network. BSBE is focused on the R&D of IVD products and has a highly qualified R&D team. Under the guidance of the experts, BSBE has established a clinical biochemistry platform using methods such as enzymatic (including enzymatic cycling method), immunoturbidimetric, latex immunoturbidimetric, CEDIA, and EMIT method; Additionally, BSBE possesses a strong R&D team specializing in liquid coagulation reagents. In 2018, the launch of blood typing system based on DG Gel card technology marked a significant step for BSBE, signaling its official entry into the field of blood type and blood matching testing. In the realm of tumor pathology, the company's products encompass essential reagents and automated immunohistochemistry staining systems for routine tumor pathology diagnosis and differential diagnosis in hospital pathology departments. Furthermore, the company has established molecular pathology testing reagents and instrument research platforms, including single monoclonal antibody preparation technology, fully automated pathological testing systems, and fluorescence in situ hybridization, actively expanding into the field of molecular pathology diagnostics and exploring diversified services and technological pathways. The company's research and development center holds the status of a National Enterprise Technology Center and is designated as the "Beijing Engineering Laboratory for Clinical Biochemistry and Immunoassay Reagents." Additionally, the company is a collaborative partner and manufacturer for the national reference material CysC, undertaking various projects under the Ministry of Science and Technology and the National Development and Reform Commission. In 2021, the company's joint collaboration with the Chinese People's Liberation Army General Hospital on the project "Establishment and Application of Cardiovascular Injury Prevention and Treatment System in Military Operational Environment" received the Second Prize of the National Scientific and Technological Progress Award. In order to meet the rapid development needs, BSBE establishes an international advanced production environment and management procedures. BSBE is firmly committed to its mission of “Quality first”, providing highly qualified testing services that cover clinical biochemistry and serology. Moreover, BSBE offers diversified clinical diagnostic solutions to customers. Simultaneously, BSBE is dedicated to providing a user-friendly experience for end-users. With an after-service throughout the country, it guarantees prompt problems-solving and professional technical support. “Running with giants”. Since 2013, BSBE has entered into strategic cooperation agreement with both international and domestic well-known enterprises, such as Abbott, Roche, Hitachi and Mindray. In 2016, BSBE signed the “LICENSE, TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT” with Abbott, which notably set a precedent for China’s IVD technology exports. Over more than a decade of rapid development, BSBE has become a leading Chinese manufacturer and provider of IVD products, significantly impacting the international IVD market. “Loyalty, Integrity, Passion” serves as BSBE’s guiding principles. Presently, BSBE holds a leadership position in the Chinese IVD market and is dedicated to enhancing its products and services globally.